JAKARTA (Reuters) – Indonesia’s drug regulator on Friday approved a COVID-19 vaccine produced by China’s Sinopharm, which is due to be used in a private vaccination scheme under which companies can buy government-procured vaccines to inoculate their staff.
No detailed efficacy data of Sinopharm’s vaccine has been publicly released, but its developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), said the vaccine was 79.34% effective in preventing people from developing the disease, based on interim data.
(Reporting by Agustinus Beo Da Costa and Stanley Widianto; Editing by Ed Davies)
